Literature DB >> 1593353

Immune hemolysis, disseminated intravascular coagulation, and serum sickness after large doses of immune globulin given intravenously for Kawasaki disease.

R L Comenzo1, M E Malachowski, H C Meissner, D R Fulton, E M Berkman.   

Abstract

One week after treatment with intravenously administered immune globulin and aspirin, a child with Kawasaki disease had persistent fever and an increase in coronary artery diameter to greater than 3 mm. Two additional doses of immune globulin were given intravenously. Rapid hemolysis occurred, followed by disseminated intravascular coagulation and serum sickness. Clinicians should be aware that immune globulin preparations contain antibodies to blood-type antigens that may cause significant hemolysis and disseminated intravascular coagulation.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1593353     DOI: 10.1016/s0022-3476(05)81964-x

Source DB:  PubMed          Journal:  J Pediatr        ISSN: 0022-3476            Impact factor:   4.406


  16 in total

Review 1.  Intravenous immunoglobulin therapy in vasculitis: speculation or evidence?

Authors:  Peer Malte Aries; Bernhard Hellmich; Wolfgang Ludwig Gross
Journal:  Clin Rev Allergy Immunol       Date:  2005-12       Impact factor: 8.667

Review 2.  [Intravenous immunoglobulins in chronic idiopathic myositis].

Authors:  H Michels; G-R Burmester; F Buttgereit
Journal:  Z Rheumatol       Date:  2005-03       Impact factor: 1.372

3.  Kawasaki disease with DIC as a complication.

Authors:  V K Parvathy; A Davis Manuel; S Criton; G Rajesh
Journal:  Indian J Pediatr       Date:  2007-11       Impact factor: 1.967

Review 4.  RhIG for the treatment of immune thrombocytopenia: consensus and controversy (CME).

Authors:  Jenny M Despotovic; Michele P Lambert; Jay H Herman; Terry B Gernsheimer; Keith R McCrae; Michael D Tarantino; James B Bussel
Journal:  Transfusion       Date:  2011-10-07       Impact factor: 3.157

Review 5.  Pharmacological therapy for patients with Kawasaki disease.

Authors:  R V Williams; L L Minich; L Y Tani
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 6.  Side-effects of intravenous immune globulins.

Authors:  C Duhem; M A Dicato; F Ries
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

Review 7.  Intravenous immunoglobulin treatment in vasculitis and connective tissue disorders.

Authors:  Andreas Steinbrecher; Peter Berlit
Journal:  J Neurol       Date:  2006-09       Impact factor: 4.849

8.  Anti-DNA and antiphospholipid antibodies in IVIG preparations: in vivo study in naive mice.

Authors:  I Krause; M Blank; Y Shoenfeld
Journal:  J Clin Immunol       Date:  1998-01       Impact factor: 8.317

Review 9.  Kawasaki disease. The mystery continues.

Authors:  D J Bradley; M P Glodé
Journal:  West J Med       Date:  1998-01

10.  Acute hemolysis after high-dose intravenous immunoglobulin therapy in highly HLA sensitized patients.

Authors:  Joseph Kahwaji; Eva Barker; Sam Pepkowitz; Ellen Klapper; Rafael Villicana; Alice Peng; Robert Chang; Stanley C Jordan; Ashley A Vo
Journal:  Clin J Am Soc Nephrol       Date:  2009-10-15       Impact factor: 8.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.